| Clinical data | |
|---|---|
| Other names | ORG-30659; Exogestin; Letogestin;[1] 11-Methylene-δ15-norethisterone; 17α-Ethynyl-11-methylene-19-nor-δ15-testosterone |
| Routes of administration | By mouth |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C21H24O2 |
| Molar mass | 308.421 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Tosagestin (INNTooltip International Nonproprietary Name,USANTooltip United States Adopted Name) (developmental code nameORG-30659), also known as11-methylene-δ15-norethisterone or17α-ethynyl-11-methylene-19-nor-δ15-testosterone, is aprogestin of the19-nortestosterone group which was under development byOrganon in theUnited States andEurope as ahormonal contraceptive (in combination withethinylestradiol) and for the treatment ofmenopausal symptoms but was never marketed.[2][3][4][5][6]
Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |